Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback